Grace Therapeutics (GRCE) Expected to Announce Earnings on Thursday

Grace Therapeutics (NASDAQ:GRCE) is expected to post its Q3 2026 results before the market opens on Thursday, February 12th. Analysts expect Grace Therapeutics to post earnings of ($0.09) per share for the quarter. Interested persons are encouraged to explore the company’s upcoming Q3 2026 earning overview page for the latest details on the call scheduled for Wednesday, February 18, 2026 at 6:00 PM ET.

Grace Therapeutics (NASDAQ:GRCE) last issued its quarterly earnings results on Thursday, November 13th. The company reported ($0.15) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.03). On average, analysts expect Grace Therapeutics to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Grace Therapeutics Price Performance

Shares of GRCE opened at $3.63 on Tuesday. The firm’s 50 day moving average is $3.52 and its 200-day moving average is $3.25. The stock has a market capitalization of $56.16 million, a P/E ratio of -5.85 and a beta of 0.76. Grace Therapeutics has a 12-month low of $1.75 and a 12-month high of $3.94.

Hedge Funds Weigh In On Grace Therapeutics

An institutional investor recently bought a new position in Grace Therapeutics stock. SeaCrest Wealth Management LLC bought a new stake in Grace Therapeutics, Inc. (NASDAQ:GRCE) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The institutional investor bought 14,000 shares of the company’s stock, valued at approximately $42,000. SeaCrest Wealth Management LLC owned approximately 0.10% of Grace Therapeutics as of its most recent SEC filing. Hedge funds and other institutional investors own 6.08% of the company’s stock.

Analysts Set New Price Targets

Several research analysts have issued reports on GRCE shares. Wall Street Zen raised Grace Therapeutics to a “hold” rating in a report on Friday, January 23rd. Weiss Ratings restated a “sell (d-)” rating on shares of Grace Therapeutics in a report on Thursday, January 22nd. Two investment analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company. According to MarketBeat, Grace Therapeutics currently has an average rating of “Hold” and a consensus target price of $12.00.

About Grace Therapeutics

Grace Therapeutics, Inc (NASDAQ: GRCE) is a clinical-stage biotechnology company dedicated to the discovery and development of novel therapies for rare genetic diseases. By employing a proprietary platform that integrates advanced molecular biology and biologic engineering, the company focuses on identifying and optimizing gene-based and protein-based candidates designed to address well-defined genetic drivers of disease.

The company’s pipeline features multiple preclinical programs targeting lysosomal storage disorders and other inherited metabolic conditions.